AU Patent

AU2015203865B2 — Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members

Assigned to Novartis AG · Expires 2016-11-03 · 10y expired

What this patent protects

H:\rec\Internoven\NRPortbl\DCC\REC\7671996_I.docx- 13/04/2015 The use of compounds of formula (I), in the treatment of Epidermal Growth Factor Receptor (EGFR) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compo…

USPTO Abstract

H:\rec\Internoven\NRPortbl\DCC\REC\7671996_I.docx- 13/04/2015 The use of compounds of formula (I), in the treatment of Epidermal Growth Factor Receptor (EGFR) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said diseases, combinations of said compounds with EGFR modulators for said use, methods of treating said diseases with said compounds and pharmaceutical preparations for the treatment of said diseases comprising said compounds alone or in combination, especially with an EGFR modulator.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015203865B2
Jurisdiction
AU
Classification
—
Expires
2016-11-03
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.